medigraphic.com

2012, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (5)

Ocular findings in children with mucopolysaccharidosis

Campos-Campos LE, Pérez-Torres V, Villavicencio-Torres A, González-Vite M

Language: Spanish
References: 20
Page: 523-528
PDF size: 181.05 Kb.


ABSTRACT

Objective: to describe the ocular findings in children with mucopolysaccharidosis at the Ophtalmology department.
Methods: clinical, descriptive, retrospective, transversal, and observational study was done. The cohort included patients under 16 years old, treated at the Hospital General, Centro Médico Nacional La Raza, with diagnosis of mucopolysaccharidosis. The variables were age, gender, damaged eye, visual acuity, ocular findings, type of mucopolysaccharidosis.
Results: there were 11 patients with mucopolysaccharidosis, 10 of them (90.9 %) full filled the inclusion criteria; nine were men. Mean age was 5.5 ± 2.8 years. There were ocular findings in both eyes in 60 % of the patients, 10 % of them in just one eye. The most frequent finding was corneal opacity (70 %), bilateral in 85.7 %, and in a single eye in 14.3 %. The ocular findings (40 %) were common in mucopolysaccharidosis type I.
Conclusions: there is visual sequels secondary to mucopolysaccharidosis. It is important to study the ocular disorders in order to treat it timely and give to patients the immediate rehabilitation to improve the quality of life.



REFERENCES

  1. Sanjurjo-Crespo P, Aldámiz-Echeverría L, Baldellou-Vázquez A. Síntomas guía de las enfermedades lisosomales. Una orientación para el pediatra general. Acta Pediatr Esp 2005; 63(6):243-247.

  2. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108(11);1299-1301.

  3. Hoffmann B, García-de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease. J Med Genet 2005;42(3):247-252.

  4. Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg 2001; 83-A(5):748-762.

  5. Alentado-Morell N, Escrig-Fernández R, Dalmau-Serra J. Enfermedad de Gaucher tipo I: 10 años de experiencia en el tratamiento enzimático sustitutivo. Acta Pediatr Esp 2005;63 (9):373-376.

  6. Connock M, Burls A, Frew E, Fry-Smith A, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review. Health Technol Assess 2006;10(24):iii-iv, ix-136.

  7. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8(5):267-288.

  8. Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, et al. Diagnosis of glycogenosis type II. Neurol 2008;71(23 Suppl 2):S4-S11.

  9. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010;362(15):1396-1406.

  10. Rodríguez SF, Gómez TA. Mucopolisacaridosis. Salud UIS 2003;35(3):135-144. Disponible en http://revistas.uis.edu. co/index.php/revistasaluduis/article/view/716

  11. Sifuentes M, Dorosh R, Hoft R, et al. Estudio de seguimiento de pacientes con MPS I tratados mediante terapia de reemplazo enzimático con laronidasa durante 6 años. J Inher Metab Dis 2007;90(2).

  12. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344(3):182-188.

  13. Amartino H, Barreiro C, Cozzo V, Czornyj L, Drelichman G, et al. Consenso de diagnóstico y tratamiento de la mucopolisacaridosis tipo I. Arch Argent Pediatr 2008;106(4):361-368.

  14. Muenzer J, Wraith JE, Clarke LA; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatr 2009;123(1);19-29.

  15. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006;51(6):1- 17.

  16. Vijay S, Wraith E. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Act Ped 2005;94(7):872-877.

  17. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8(8):465-473.

  18. Suárez-Obando F, Zarante-Montoya I. Aspectos clínicos y manejo integral del síndrome de Morquio. Univers Med 2007;48(2):166-174. Disponible en http://redalyc.uaemex. mx/redalyc/pdf/2310/231018666010.pdf

  19. Kottler U, Demir D, Schmidtmann I, Beck M, Pitz S. Central corneal thickness in mucopolysaccharidosis II and VI. Cornea 2010;29(3):260-262.

  20. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120 (2);405-418.




2020     |     www.medigraphic.com